The addition of durvalumab and olaparib to paclitaxel neoadjuvant chemotherapy exhibited better clinical efficacy in a phase II I-SPY2 trial (NCT01042379) over paclitaxel neoadjuvant chemotherapy in HER2 − breast cancer, mainly in serious HR + and HER2 − patients [183]. This evidence concerns the gene ERBB2 and breast cancer.